Meeting
2015 Genitourinary Cancers Symposium
Results of the phase I trial of cetuximab with mitomycin c and 5-fluorouracil concurrent with radiotherapy treatment in patients with muscle-invasive bladder cancer.
Authors
Syed A. Hussain
University of Liverpool, Clatterbridge Cancer Centre, Liverpool, United Kingdom
Syed A. Hussain , Carey Hendron , Laura Buckley , Lynne Dickinson , Isabel Syndikus , Zafar Malik , Chinnamani Eswar , Nicholas David James
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Prostate, Penile, Testicular, and Urethral Cancers, and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Urothelial Carcinoma
Clinical Trial Registration Number
NOT KNOWN
Citation
J Clin Oncol 33, 2015 (suppl 7; abstr 368)
DOI
10.1200/jco.2015.33.7_suppl.368
Abstract #
368
Poster Bd #
H5
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Phase I/II trial of cetuximab with 5-fluorouracil and mitomycin C concurrent with radiotherapy in patients with muscle invasive bladder cancer.
First Author: Syed A. Hussain
Poster
2020 Genitourinary Cancers Symposium
A phase I/II feasibility study of cetuximab with 5FU and mitomycin C or cisplatin with concurrent radiotherapy in muscle invasive bladder cancer.
First Author: Nicholas D. James
Poster
2024 ASCO Genitourinary Cancers Symposium
Phase 3 KEYNOTE-992 study of pembrolizumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with muscle-invasive bladder cancer (MIBC).
First Author: Shilpa Gupta
Poster
2022 ASCO Annual Meeting
Safety and tolerability of olaparib combined with breast radiotherapy in patients with triple-negative breast cancer: Final results of the RADIOPARP phase 1 trial.
First Author: Pierre Loap